- Home
- SXTC vs AARD Comparison
SXTC vs AARD Comparison
Compare SXTC & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTC
- AARD
- Stock Information
- Founded
- SXTC 2005
- AARD 2017
- Country
- SXTC China
- AARD United States
- Employees
- SXTC N/A
- AARD N/A
- Industry
- SXTC Biotechnology: Pharmaceutical Preparations
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- SXTC Health Care
- AARD Health Care
- Exchange
- SXTC Nasdaq
- AARD Nasdaq
- Market Cap
- SXTC 164.8M
- AARD 186.3M
- IPO Year
- SXTC 2019
- AARD 2025
- Fundamental
- Price
- SXTC $1.90
- AARD $11.29
- Analyst Decision
- SXTC
- AARD Strong Buy
- Analyst Count
- SXTC 0
- AARD 5
- Target Price
- SXTC N/A
- AARD $32.60
- AVG Volume (30 Days)
- SXTC 860.1K
- AARD 203.4K
- Earning Date
- SXTC 01-01-0001
- AARD 11-14-2025
- Dividend Yield
- SXTC N/A
- AARD N/A
- EPS Growth
- SXTC N/A
- AARD N/A
- EPS
- SXTC N/A
- AARD N/A
- Revenue
- SXTC $1,740,907.00
- AARD N/A
- Revenue This Year
- SXTC N/A
- AARD N/A
- Revenue Next Year
- SXTC N/A
- AARD N/A
- P/E Ratio
- SXTC N/A
- AARD N/A
- Revenue Growth
- SXTC N/A
- AARD N/A
- 52 Week Low
- SXTC $0.95
- AARD $4.88
- 52 Week High
- SXTC $7.84
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- SXTC 60.38
- AARD N/A
- Support Level
- SXTC $1.33
- AARD N/A
- Resistance Level
- SXTC $1.97
- AARD N/A
- Average True Range (ATR)
- SXTC 0.21
- AARD 0.00
- MACD
- SXTC 0.05
- AARD 0.00
- Stochastic Oscillator
- SXTC 81.91
- AARD 0.00
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.